No clinical benefit of intramuscular delivery of bone marrow-derived mononuclear cells in nonreconstructable peripheral arterial disease: results of a phase-III randomized-controlled trial. Ann Surg 2018; 268: 756-761.

Published: 19th December 2018

Authors: Lindeman J, Zwaginga J, Kallenberg-Lantrua G, van Wissen RC, Schepers A, van Bockel HJ et al.


Fifty-four patients with unreconstructable vascular disease without imminent need for amputation were included. There was no obvious effect on walking distance, quality of life or amputation rates between the groups.

Pubmed Link

Your comments